To confirm this, Imatinib, a Food and Drug Administration (FDA)–approved tyrosine kinase inhibitor (TKI) targeting BCR-ABL optimized for chronic myelogenous leukemia (CML), exhibited an inhibitory effect against IRE1α activity [10]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.